Prostate cancer: risk of death may be raised by Western diet
6/01/2015
Researchers suggest that a diet high in red and processed meats, refined grains and high-fat dairy products could lead to an increased risk of death for prostate cancer patients.
Study identifies possible new combination chemotherapy for patients with advanced prostate cancer
6/01/2015
For more than a decade, oncologists using cytotoxic chemotherapy to treat patients with advanced metastatic castration-resistant prostate cancer (mCRPC) have relied on the sequential use of single...
Combining targeted drug with chemotherapy offers longer life to b-cell cancer patients
6/01/2015
Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an...
Study shows colorectal cancer genetically different in older and younger patients
6/01/2015
While the overall rate of colorectal cancer (CRC) is declining, CRC specifically among young patients is increasing.
Genetic biomarker may predict cancer patients' response to immunotherapy drug
6/01/2015
In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in...
Pembrolizumab shows real promise against head and neck cancer
6/01/2015
Biomarker reliably predicts which patients will not benefitThe cancer (red and blue) is infiltrated with immune cells (green), which can attack and kill cancer.
Study shows sexual dysfunction after gynecologic cancer treatment
6/01/2015
A University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 shows decreased sexual activity in women following treatment for...
ESMO announces scale to stratify magnitude of clinical benefit of anticancer medicines
6/01/2015
ESMO, the European Society for Medical Oncology, has announced the publication of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS)1, a tool to assist oncology clinicians in evaluating the...
Myriad presents new myRisk hereditary cancer data at 2015 ASCO Annual Meeting
6/01/2015
Myriad myRisk finds >60 percent more mutations than BRCA1/2 testing in multiple studiesMyriad Genetics, Inc.
ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'
6/01/2015
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast...